Ask A Digital Health Investor: Canaan’s Kjellson On Smart Strategies
Digital health encompasses a motley crew of companies from single-app start-ups to long-established software specialists. Nina Kjellson, general partner at Canaan Partners, makes it her business to sort the wheat from the chaff and make smart investments that will pay off for the VC.
You may also be interested in...
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.